GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

1 Apr 2009 08:10

RNS Number : 8916P
ViaLogy PLC
01 April 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY") 

VIALOGY INCREASES STAKE IN SUCCESSFUL WELL

LONDONApril 1st, 2009 - ViaLogy PLC (LSE: VIY). ViaLogy announces that it has exercised an option with Atascosa Exploration LLC, of San Antonio, Texas ("Atascosa") to acquire an increased shareholding in the Galba Prospect oil well in South Central Texas ("Cindy Bartlett #2") found in March 2009 using its QuantumRD technology. ViaLogy now owns a 10% direct working interest in the Cindy Bartlett #2 well with revenue to ViaLogy expected to begin in Q2 this year. This means that ViaLogy will receive 10% of the Net Revenue Interest of the well over its lifespan. The amount of oil in the well has been calculated using industry standard core analysis practices.

 

ViaLogy has also agreed terms and dates with Atascosa for the near-term drilling of a second well on the Galba Prospect in south central Texas. Using ViaLogy's patented QuantumRD technology, the Company's scientists and Atascosa's geology and engineering team will immediately examine 3D seismic data and QuantumRD analysis to decide the optimum location position for the drilling rig. Spudding of the second well is expected to start within weeks.

ViaLogy's increased holding in Cindy Bartlett #2, and the drilling of the new well, to be called Cindy Bartlett #3, further cements the relationship with Atascosa following the success of QuantumRD which was announced on 23 March 2009 on the discovery of a series of three new oil formations at increasing depths on the Galba Prospect. The first well on the site, Cindy Bartlett #2, was drilled into the formation lying at 3,100 feet. Use of the QuantumRD seismic interpretation technology verifies the presence of hydrocarbons, permits characterization of the reservoir and porosity, and siting of the drill location. The technology is based on protected active signal processing software capable of exploiting the "noise" inherent in most seismic data. 

 

"For the immediate future we are focussing our activities on Texas," said ViaLogy's Chief Executive, Robert W. Dean. "We have a new technology that is proving its ability to improve the ratio of producing successful wells instead of dry holes, which for on-shore drilling in the continental USA currently occur in six cases out of ten. But the real secret is to combine our value-added ability to more effectively interpret the seismic data with the experience of geologists and oil men who know the areain which we work." 

"In this regard, over the past six months we've developed an excellent working relationship with Atascosa Exploration, and both companies have agreed to work closely together on future projects. So we welcomed the opportunity when Atascosa offered us a larger participation in the successful well we'd developed together."

 

Ends

 

For further information please contact:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

Atascosa Exploration LLC   John D. Mullins, CEO (+1 210-402-3656) 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)   Mark Percy +44 (0) 20-7107-8000

Broker to ViaLogy PLC (St. Helen's Capital)

Ruari McGirr / Sebastian Wykeham +44 (0) 207 628 5582 

 

About ViaLogy: 

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUUUMUCUPBUMG
Date   Source Headline
11th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
11th Jul 20239:33 amRNSForm 8.5 (EPT/RI) - Yourgene Health PLC
10th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
10th Jul 202311:44 amRNSForm 8.3 - Yourgene Health plc
10th Jul 202311:10 amRNSForm 8.3 - Yourgene
10th Jul 202310:10 amRNSForm 8.5 (EPT/RI)
10th Jul 20238:21 amRNSForm 8.3 - Yourgene Health PLC
7th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
7th Jul 202311:40 amRNSForm 8.5 (EPT/RI)
6th Jul 20232:00 pmRNSForm 8.3 - Yourgene Health plc
6th Jul 20231:00 pmRNSForm 8.5 (EPT/RI) - Replacement
6th Jul 202312:01 pmRNSForm 8.5 (EPT/RI)
6th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
6th Jul 20237:00 amRNSForm 8.3 - Yourgene Health PLC
5th Jul 20234:04 pmRNSForm 8.3 - Yourgene Health plc
5th Jul 20233:46 pmRNSFORM 8.3 - Yourgene Health Plc
5th Jul 20232:03 pmRNSForm 8.3 - Yourgene Health plc
5th Jul 20231:27 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc Amended
5th Jul 202312:30 pmRNSForm 8.3 - Yourgene Health Plc
5th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
5th Jul 202311:22 amRNSForm 8.3 - Yourgene Health plc
5th Jul 202311:03 amRNSForm 8.3 - YOURGENE HEALTH PLC
5th Jul 202310:33 amRNSForm 8.3 - Yourgene Health PLC
5th Jul 202310:23 amRNSForm 8.5 (EPT/RI)
4th Jul 20236:28 pmRNSForm 8.3 - Yourgene Health PLC
4th Jul 20235:41 pmRNSForm 8.3 -Yourgene Health plc
4th Jul 20234:53 pmRNSForm 8.3 - YourGene Health Plc
4th Jul 20233:57 pmRNSForm 8.3 - Yourgene Health plc
4th Jul 20232:26 pmRNSForm 8.3 - Yourgene Health plc
4th Jul 20231:56 pmRNSForm 8.3 - Yourgene Health plc
4th Jul 20231:56 pmRNSHolding(s) in Company
4th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
4th Jul 202311:57 amRNSForm 8.5 (EPT/RI)
4th Jul 20238:50 amRNSForm 8.3 - Yourgene Health PLC
3rd Jul 20234:04 pmRNSForm 8.3 - Yourgene Health PLC
3rd Jul 20237:00 amRNSRule 2.7 Announcement
13th Jun 20238:30 amRNSConditional disposal of Taiwan laboratory
6th Jun 202310:21 amRNSHolding(s) in Company
22nd May 20237:01 amRNSYGS to support MHC’s Boots agreement
22nd May 20237:00 amRNSDirectorate Change
5th May 202310:14 amRNSHolding(s) in Company
2nd May 20231:11 pmRNSHolding(s) in Company
27th Apr 20237:00 amRNSFull year unaudited trading update
18th Apr 20234:07 pmRNSHolding(s) in Company
31st Mar 20234:08 pmRNSHolding(s) in Company
24th Mar 20234:57 pmRNSHolding(s) in Company
17th Mar 20237:00 amRNSDirectorate Change
13th Mar 20237:00 amRNSStatement re. Silicon Valley Bank
21st Feb 202312:00 pmRNSChange of Website
27th Jan 20237:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.